With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.294-90-6,1,4,7,10-Tetraazacyclododecane,as a common compound, the synthetic route is as follows.
To a suspension of cyclen (500 g, 29 rnrnol) and sodium acetate (7.86 g, 96 mrnol) in N,N-dirnethylacetarnide (DMA, 60 rnL) at 2O C was added a solution of t-butyl bromoacetate (18.7 g, 14.1 mL, 96 mmol) in DMA (20 rnL) dropwise over a period of 0.5 h. The temperature was maintained at -20 C during the addition, after which the reaction mixture was allowed to come to room temperature. After 24 h of vigorous stirring, thereaction mixture was poured into water (300 rnL) to give a clear solution. Solid KHCO3 (15 g, 150 rnrnol) was added portion wise, and 4 precipitated as a white solid. The precipitate was collected by filtration and dissolved in CHCI3 (250 mL). The solution was washed with water (100 mL), dried (MgSO4), filtered, and concentrated to about 2O3O tnL. Ether (250 mE) was added, after which HHY-330 crystallized as a white fluffy solid.Yield: 12.5 g (73%). ESI-MS found: [M+Ht = 515.5 (Moore, D. A. Org. Synth. 2008, 85,1O-14).
294-90-6, The synthetic route of 294-90-6 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; SANOFI; EUROPEAN MOLECULAR BIOLOGY LABORATORY; HU, Hai-Yu; NAZARE, Marc; HAN LIM, Ngee; DING-PFENNIGDORFF, Danping; PLETTENBURG, Oliver; RITZELER, olaf; JURETSCHKE, Hans-Paul; SAAS, Joachim; BARTNIK, Eckart; FLORIAN, Peter; WENDT, Ulrich; SCHULTZ, Carsten; NAGASE, Hideaki; WO2015/75699; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI